Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia

作者
Jason C. Yeh,Rima M. Saliba,Christopher Wang,Zhou Fang,Bradley Figgins,Sairah Ahmed,Musa E. Yilmaz,Naval Guastad Daver,Rohtesh S. Mehta,Gheath Alatrash,David Marin,Uday Popat,Richard E. Champlin,Elizabeth J. Shpall,Betül Oran
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 7686-7688 被引量:3
标识
DOI:10.1182/blood-2022-165780
摘要

Background: Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) AML is associated with an increased risk of relapse, leading many patients to receive an allogeneic hematopoietic stem cell transplantation (HCT) after induction therapy. Unfortunately, relapse after HCT remain high and strategies are needed to improve outcomes. The SORMAIN trial has demonstrated survival benefit with sorafenib (SORA) maintenance after HCT in FLT3-ITD AML. Gilteritinib (GILT) is a second generation FLT3 inhibitor with efficacy in FLT3-ITD AML and higher FLT3 potency compared to other FLT3 inhibitors. Our institution utilizes GILT and SORA, per physician's preference, as post-HCT maintenance in all FLT3-ITD AML. In this study, we aim to compare efficacy and safety between GILT and SORA as post-HCT maintenance. Methods: We performed a retrospective analysis of adult patients with FLT3-ITD AML who received allogenic HCT from 6/1/2016 to 12/31/2020 and thereafter received SORA or GILT as post-HCT maintenance (off clinical trial). Patients included were in complete remission (CR) after HCT at the time of initiation. Primary outcome was 1-year progression-free survival (PFS) after initiation of maintenance. Secondary outcomes included overall survival (OS), non-relapse mortality (NRM), relapse, and adverse events (AE) 1 year after maintenance was started. AEs observed were collected retrospectively by chart review and classified according to CTCAE criteria. Results: A total of 55 patients were treated with either GILT (n=27) or SORA (n=29) for post-HCT maintenance. One patient was treated with SORA after first HCT and GILT after second HCT. Patient characteristics, as presented in Table 1, were comparable between groups. FLT3 inhibitors were utilized in pre-HCT therapy in all but 1 patient. Median time to initiation of GILT was 60 days (range, 21-233) after HCT and the most common starting dose was 40 mg/day. Median duration of time that patients remained on GILT was 385 days (range, 10-804). Median time to start SORA was 58 days (range, 31-191) after HCT and the most common starting dose was 200 mg/day. Median duration of time that patients remained on SORA was 315 days (range, 3-1777). Median follow-up time of survivors was 16 and 33 months in the GILT and SORA groups respectively. As shown in Figure 1, 1-year PFS and relapse incidence were similar between GILT and SORA; PFS was 66% vs. 76% (p=0.4) and relapse incidence was 19% vs. 24% (p=0.6), respectively. OS at 1 year, 78% vs. 83% (p=0.4), was also comparable. However, NRM at 1 year was higher in the GILT group, 15% vs 0% in the SORA group (p=0.03). Causes of death in the GILT group (n=4) included 1 diffuse alveolar hemorrhage and 3 pneumonias (2 viral and 1 interstitial). As presented in Table 1, both groups had high incidence of Grade 3-4 neutropenia, anemia, and thrombocytopenia. This was followed by liver toxicity (39% vs. 38% in SORA and GILT groups) and infections (38% in both groups). As expected, there was higher incidence of skin toxicity in the SORA group compared with GILT (28% vs. 7%, p=0.09). GVHD rates appeared comparable. Although the intention was to give maintenance for 1 year, 13 patients (48%) in the GILT group and 15 patients (52%) in the SORA group discontinued maintenance before completion of 1 year. Reasons included relapse (n=5), cytopenias (n=2), pulmonary toxicity (n=2), cardiac toxicity (n=1), GI toxicity (n=1), eosinophilia (n=1), and viral infection (n=1) in the GILT group and relapse (n=6), cytopenias (n=6), skin toxicity (n=2), and liver toxicity (n=1) in the SORA group. Four patients switched from SORA to GILT but none switched from GILT to SORA. Conclusions: Our results revealed comparable PFS, OS, and relapse incidence when SORA and GILT are used as post-HCT maintenance therapy. Both drugs were associated with high incidence of grade 3-4 cytopenias. Despite similar toxicity profile with GILT and SORA, 1-year NRM in the GILT group was higher than the SORA group. Higher incidence of HCT-CI ≥ 3 in the GILT group may have contributed to this difference. Since our analysis was retrospective and AEs were not collected in real time, the attribution of observed AEs to the maintenance drug could not be assessed and captured. Therefore, we cannot provide an explanation of the higher NRM after GILT despite similar documented AEs. We await the results from BMTCTN 1506 that would provide more insight to the efficacy and tolerability of GILT in the post-HCT setting. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
YongLiu完成签到,获得积分10
刚刚
loong关注了科研通微信公众号
1秒前
踏实博超发布了新的文献求助10
1秒前
1秒前
思源的应助被pp采纳,获得10
1秒前
ZXL666关注了科研通微信公众号
1秒前
yly发布了新的文献求助10
2秒前
年轻雁枫发布了新的文献求助10
2秒前
3秒前
可靠碧萱完成签到,获得积分20
3秒前
4秒前
4秒前
5秒前
5秒前
5秒前
chowjb完成签到,获得积分10
5秒前
Owen的应助被之之采纳,获得100
5秒前
我是谁的应助被vbmc采纳,获得30
6秒前
8秒前
8秒前
哭泣冬瓜发布了新的文献求助10
8秒前
Owen的应助被波纹疾走打字机采纳,获得10
9秒前
9秒前
wuwu发布了新的文献求助10
9秒前
想杀鸡发布了新的文献求助10
10秒前
邹国嵩完成签到,获得积分10
10秒前
无限完成签到 ,获得积分10
10秒前
MRCHONG发布了新的文献求助10
10秒前
小SCI发布了新的文献求助10
11秒前
hhhhh发布了新的文献求助10
11秒前
科研通AI6.2的应助被雅风采纳,获得10
11秒前
领导范儿的应助被lzq采纳,获得10
12秒前
檀兮尔发布了新的文献求助10
12秒前
深情安青的应助被许右采纳,获得10
13秒前
13秒前
13秒前
余又发布了新的文献求助10
13秒前
13秒前
shery完成签到,获得积分10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611